

## Recalibration of the HAS-BLED score

Nielsen, Peter Brønnum; Larsen, Torben Bjerregaard; Lip, Gregory Y.h.

DOI:  
[10.1378/chest.15-1509](https://doi.org/10.1378/chest.15-1509)

License:  
Unspecified

Document Version  
Peer reviewed version

Citation for published version (Harvard):  
Nielsen, PB, Larsen, TB & Lip, GYH 2016, 'Recalibration of the HAS-BLED score: should hemorrhagic stroke account for one or two points?', *Chest*, vol. 149, no. 2, pp. 311-314. <https://doi.org/10.1378/chest.15-1509>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy


While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Accepted Manuscript

Recalibration of the HAS-BLED score – should haemorrhagic stroke account for 1 or 2 points?

Peter Brønnum Nielsen, MSc, PhD, Torben Bjerregaard Larsen, MD, PhD, Gregory Y.H. Lip, MD



PII: S0012-3692(15)00013-6

DOI: [10.1378/chest.15-1509](https://doi.org/10.1378/chest.15-1509)

Reference: CHEST 12

To appear in: *CHEST*

Received Date: 24 June 2015

Revised Date: 7 July 2015

Accepted Date: 17 July 2015

Please cite this article as: Nielsen PB, Larsen TB, Lip GYH, Recalibration of the HAS-BLED score – should haemorrhagic stroke account for 1 or 2 points?, *CHEST* (2015), doi: 10.1378/chest.15-1509.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Word count main text:** 1457

**Word count abstract:** 244

## COMMENTARY

### **Recalibration of the HAS-BLED score – should haemorrhagic stroke account for 1 or 2 points?**

Peter Brønnum Nielsen, MSc, PhD<sup>1</sup>

Torben Bjerregaard Larsen, MD, PhD<sup>1</sup>

Gregory Y.H. Lip, MD<sup>1,2</sup>

1.Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

2.University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

**Running title:** Recalibration of the HAS-BLED score

**Correspondence to:** Prof GYH Lip.

g.y.h.lip@bham.ac.uk

#### **Funding and role of the sponsor:**

The Obel Family Foundation partly funded this research by an unrestricted grant. The sponsor had no role the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

**Disclosures**

Professor Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer and Boehringer Ingelheim, and has been on the speaker bureaus for Bayer, BMS/Pfizer, Boehringer Ingelheim and Sanofi. Associate Professor Larsen has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim, and has been on the speaker bureaus for Bayer, BMS/Pfizer, Roche Diagnostics, Boehringer Ingelheim and Takeda Pharma. Other authors – none declared

**Abstract**

Following a haemorrhagic stroke, it is uncertain whether this event scores 1 point (either for Stroke or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a haemorrhagic stroke.

We analysed data from the Danish nationwide cohort of incident atrial fibrillation (AF) patients from January 1999 to December 2013. The primary outcome in this observational study was major bleeding. The original- and the recalibrated HAS-BLED scores were assessed and event rates of major bleeding were calculated. We compared the predictive accuracy of major bleeding by C-statistics, the Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI).

In a total of 210,299 AF patients, we observed an event rate for major bleeding of 4.3 per 100 person-years. The C-statistics for the two scores were modest: 0.613 (95% CI, 0.607-0.619) for the original and 0.616 (95% CI, 0.610-0.622) for the recalibrated. The NRI was 10.0% (95% CI 7.6%-12.4%). When assessing the NRI in less than 6 months follow-up, we observed a markedly higher NRI of 34.2%. The relative IDI was 23.6% (95% CI, 15.7%-31.5%) reflecting that the recalibrated HAS-BLED score more accurately predicted bleeding events.

Recalibration of the “S” component in the HAS-BLED score, counting 2 points for a haemorrhagic stroke, resulted in an increase in the C-statistics, NRI and IDI. This approach could potentially aid physicians in a more accurate bleeding risk assessment in AF patients.

## Introduction

Oral anticoagulant (OAC) treatment substantially reduces the risk of stroke and all-cause mortality in atrial fibrillation (AF) patients.<sup>1</sup> However, the decision to treat these patients relies on the expected risk of stroke weighed against the expected risk of bleeding. Contemporary guideline recommendations on OAC treatment are based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score (assessing the risk of thromboembolism) to initiate treatment or not.<sup>2,3</sup> The European Society of Cardiology further recommends formal assessment of the bleeding risk by the HAS-BLED score.<sup>4</sup> The HAS-BLED score summarizes to a maximum of 9 points (hypertension, abnormal renal/liver function [1 or 2 points], stroke, bleeding history or predisposition, labile INR, elderly [ $>65$ ], drugs/alcohol concomitantly [1 or 2 points]).<sup>5</sup> A stroke currently contributes 1 point, and prior major bleeding (or its predisposition) contributes 1 point. Accurate bleeding risk assessment and optimal treatment guidance is pivotal in this frail population of AF patients who sustain an intracranial bleeding, especially given the strong associations to disability and mortality.<sup>6,7</sup>

Following a haemorrhagic stroke, it is unclear whether it should count 1 point (either for Stroke or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a haemorrhagic stroke.

## Methods and materials

We used data from three Danish nationwide registries to conduct an observational cohort study investigating the original HAS-BLED score and the recalibrated HAS-BLED score. As previously done, we identified nonvalvular AF patients discharged from hospital from January 1<sup>st</sup> 1999 to December 31<sup>st</sup> 2013, and excluded patients who encountered a thromboembolism or major bleeding within 7 days after discharged.<sup>8</sup> The primary endpoint was major bleeding defined as a composite of intracranial bleeding (including traumatic intracranial bleeding events), gastrointestinal bleeding, acute anemia, bleeding from the urinary tract, and airway bleeding; see supplemental e-Table 1 for ICD-10 codes. Both primary and secondary diagnoses were included, but emergency room diagnoses were not included due to low validity.<sup>9</sup> We followed the patients from 7 days after hospital discharge and up to one year later or to occurrence of death, a major bleeding event, or end-of-study period, whichever came first.

We calculated two different HAS-BLED scores (original and recalibrated) at hospital discharge; only patients with a haemorrhagic stroke (non-traumatic intracranial bleeds) were reclassified in the recalibrated HAS-BLED score. Crude event rates (total number of events divided by accrued person-time) stratified by score ranging from 0-8 were reported. We did not have information on INR values; hence the “L” component was excluded from the calculations. To compare the predictive power of the scores we calculated and compared the (Harrell’s) C-statistics.<sup>10</sup> We obtained estimates of bleeding risk in a competing risk of death setting, by using information directly from the cumulative incidence function.<sup>11</sup> Use of competing risk analyses are advised - especially in an elderly and fragile population - to obtain adequate risk estimates, which are not biased due to the competing risk.<sup>12</sup> To further compare the individual level changes in risk assessment from the two scores, we calculated a Net Reclassification Index (NRI), also in a competing risk setting.<sup>13,14</sup> In short, the NRI evaluates the proportion of patients with a

correct/incorrect change in risk according to being a case (patient with an event) or a non-case.

Finally, we calculated the Integrated Discrimination Improvement (IDI) relative to the original HAS-BLED score to assess the separation in predicted risk for events and non-events.<sup>15</sup> Bootstrap confidence intervals (CI) for C-statistics, NRI and IDI were calculated using 100 bootstrap samples. Data were analysed using Stata version 13.1 (Stata Corporation, College Station, TX). Register-based studies do not require ethical approval in Denmark.

We performed three sensitivity analyses, as follows: 1) stratifying patients according to baseline OAC treatment or initiation within the first 7 days after baseline. This was done in an attempt to indirectly assess if the missing “L” component from the data could influence the results (recognizing that patients not treated with OAC would not contribute to this component); 2) restricting the follow-up time to 6 months to assess performance of the recalibrated HAS-BLED compared to the original HAS-BLED in (relatively) short follow-up time. The motivation for this analysis was established by conceding an intracranial haemorrhage can be associated with increased event rates of recurrent major bleeding (including recurrent intracranial bleeding)<sup>16</sup>; and 3), we restricted the study period to the five most recent calendar years (2009-2013). Given the increasing availability of imaging technologies (MRI/CT scans) in this period, the validity of haemorrhagic stroke and/or haemorrhagic bleedings diagnosis were deemed to increase; hence, the proportion of reclassified patients (based on haemorrhagic stroke) would be more accurate.



## Results

The study population comprised 210,299 AF patients (5,898 patients were excluded due to a thromboembolic/bleeding event within 7 days after discharge) with a median age of 74 [IQR: 65-82] and 46.6% were women. During one year of follow-up we observed 7,602 (3.62%) bleeding events. The mean HAS-BLED scores were 2.13 for the original score and 2.14 for the recalibrated score. The overall crude event rate of the primary endpoint was 4.3 per 100 person-years; Table 1 shows the event rates stratified according to points for the two scores. A total of 1,479 patients were reclassified in the recalibrated HAS-BLED score based on having sustained a haemorrhagic stroke when the observation time commenced. The predictive accuracy of the two scores in terms of the C-statistics was moderate, 0.613 (95%CI, 0.607-0.619) for the original and 0.616 (95%CI, 0.610-0.622) for the recalibrated HAS-BLED score, respectively. The NRI was 10.0% (95%CI, 7.6%-12.4%) displaying a significant improvement of correct classification by the recalibrated HAS-BLED score compared to the original score. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) reflecting that the recalibrated HAS-BLED score more accurately predicted bleeding events.

When stratifying the cohort to patients who received no OAC treatment vs treated, we saw an increase in the bleeding rates per 100 person-years: 3.97 for no treatment and 4.73 for OAC treated. The sensitivity analysis resulted in similar NRI: for OAC treated 9.0% (95%CI, 4.8%-12.3%) and for not treated 10.1% (95%CI, 9.0%-11.2%). The C-statistics were likewise not affected by this stratification [data not shown]. When applying shorter follow-up period (i.e. 6 months), we observed a considerably higher NRI of 35.0% (95%CI, 32.9%-37.1%). The C-statistics for original and recalibrated HAS-BLED score, however, displayed a modest increase, 0.617 and 0.621, respectively. Restricting the study period to the last five years reduced the study population to 78,699 patients, and essentially doubled the NRI: 20.7% (95%CI, 17.9%-23.5%).

## Discussion

In this nationwide cohort study reflecting clinical practice, we recalibrated the original HAS-BLED score to account for 2 points if the stroke type was a haemorrhagic stroke. We observed an improved accuracy of the recalibrated HAS-BLED score as displayed by an improved NRI of 10.0% and a relative IDI of 23%.

Although the recalibration only resulted in a modest increase in the C-statistics, the potential of improved accuracy could be higher, as we only reclassified a very small proportion of this large cohort: of 2,218 patients who sustained an ICH event, we reclassified 1,479 (0.7% of total study population). The remaining 739 patients who were not reclassified all had prior events of ischemic stroke/TIA and a major bleeding event (or anaemia).

The recalibrated HAS-BLED score could potentially be more complicated to count than the original score. The physician who is presented with a patient who has sustain an haemorrhagic stroke has to take into account if this patient already has 1 point attributing prior bleeding and prior stroke. On the other hand, counting a haemorrhagic stroke as two points (1 for stroke and 1 for bleeding) appears intuitively applicable given the nature of the outcome. Importantly, the recalibrated score performs best within short follow-up time in terms of NRI, which could be related to the patients who were actually reclassified (those with a haemorrhagic stroke); however, this could represent the early excess risk associated with such 'high risk' patients.

This study has some limitations. We did not have access to INR values from the registries; hence we excluded a potential pivotal component from the HAS-BLED score. We used an observational design to assess the HAS-BLED score, but we cannot rule out miscoding of comorbidity and concomitant medication. Additionally, we did not have access to imaging data and we cannot rule out erroneously coded haemorrhagic strokes. We assessed the HAS-BLED score at baseline,

however risk assessment in AF patients is a continuum and risk (both for bleeding and thromboembolic events) does not remain static in these patients.

In conclusion, recalibration of the HAS-BLED score, counting 2 points for a haemorrhagic stroke, resulted in an improved accuracy of predicting major bleeding events. This approach could potentially aid physicians in a more accurate bleeding risk assessment in AF patients.

**References**

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;146(12):857–67.
2. Camm AJ, Lip GYH, Caterina R De, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation - Developed with the special contribution of the European Heart Rhythm Association. *Europace* 2012;14(10):1385–413.
3. January CT, Wann FLS, Joseph F, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. *J Am Coll Cardiol* 2014;64(21):2246–2280.
4. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;31(19):2369–429.
5. Pisters R, Lane DA, Nieuwlaat R, Vos CB de, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138(5):1093–100.
6. Marsh EB, Gottesman RF. Brain hemorrhage: restarting anticoagulation after intracranial hemorrhage. *Nat Rev Neurol* 2011;7(3):130–2.
7. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GYH. Restarting Anticoagulant Treatment After Intracranial Haemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality and Bleeding: A Nationwide Cohort Study. *Circulation* 2015;In press. DOI 10.1161/CIRCULATIONAHA.115.015735
8. Lip GYH, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide co. *Chest* 2014;146(5):1337–46.
9. Johnsen SP, Overvad K, Sørensen HT, Tjønneland A, Husted SE. Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. *J Clin Epidemiol* 2002;55(6):602–7.
10. Newson R. Comparing the predictive powers of survival models using Harrell's C or Somers' D. *Stata J* 2010;10(3):339–358.
11. Wolbers M, Koller MT, Wittteman JCM, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiology* 2009;20(4):555–561.

12. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy: A competing risk study. *Circulation* 2008;117(15):1918–1926.
13. Pencina MJ, D’Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med* 2011;30(1):11–21.
14. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. *Biometrics* 2005;61(1):223–229.
15. Pencina MJ, D’Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. *Clin. Chem. Lab. Med.* 2010;48(12):1703–1711.
16. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. *Mayo Clin Proc* 2007;82(1):82–92.

**Table 1:** Major bleeding event rates per 100 person-years for major bleeding events according to HAS-BLED scores for 1-year follow-up in incident atrial fibrillation patients.

Points	Original HASBLED			Recalibrated HASBLED		
	Person-time	Events	Event rate	Person-time	Events	Event rate
0	19611	193	0.98	19611	193	.98
1	41864	1127	2.69	41799	1,111	2.69
2	51933	2179	4.20	51703	2,149	4.16
3	43769	2392	5.46	43646	2,368	5.43
4	17359	1294	7.45	17472	1,316	7.53
5	3692	361	9.78	3965	402	10.14
6	425	52	12.25	456	59	12.94
7	22	4	18.23	23	4	17.36
8	12	0	-	22	0	-
9 (Labile INR)	NA	NA	NA	NA	NA	NA
Any score	178676	7602	4.3	-	-	-
Categorised risk						
0-2 (low risk)	113408	3499	3.09	113113	3453	3.05
$\geq 3$ (High risk)	65268	4103	6.29	65563	4149	6.33

Observation time starts after a quarantine period of 7 days relative to AF discharge.

**List of abbreviations:**

OAC: Oral anticoagulant

AF: Atrial fibrillation

ICD-10: International classification of disease version 10

INR: International normalized ratio

NRI: Net reclassification index

IDI: Integrated discrimination improvement

CI: Confidence interval

IQR: Interquartile range

TIA: Transient ischemic attack



If there is Online Only content that cannot be converted to a Word processing format, you may have to click the Supplemental Files icon on the menu bar in your Reviewer Center to access.

**Recalibration of the HAS-BLED score – should haemorrhagic stroke account for 1 or 2 points?**

Journal:	<i>CHEST</i>
Manuscript ID:	CHEST-15-1509.R1
Manuscript Type:	Commentary
Date Submitted by the Author:	07-Jul-2015
Complete List of Authors:	Nielsen, Peter; Aalborg University, Aalborg Thrombosis Research Unit Larsen, Torben; Aalborg University Hospital, Aalborg Hospital, Department of Cardiology & Center for Thrombosis Research; Aalborg University, Department of Clinical Medicine Lip, Gregory; City Hospital, Centre for Cardiovascular Sciences; Aalborg University, Thrombosis Research Unit, Dept of Clinical Medicine
Keywords:	STROKE, CARDIOLOGY, CLINICAL DECISION MAKING

SCHOLARONE™  
Manuscripts



**List of abbreviations:**

OAC: Oral anticoagulant

AF: Atrial fibrillation

ICD-10: International classification of disease version 10

INR: International normalized ratio

NRI: Net reclassification index

IDI: Integrated discrimination improvement

CI: Confidence interval

IQR: Interquartile range

TIA: Transient ischemic attack

1  
2  
3  
4 **Word count main text:** 1457

5  
6 **Word count abstract:** 244

7  
8 **COMMENTARY**

9  
10  
11  
12 **Recalibration of the HAS-BLED score – should**  
13 **haemorrhagic stroke account for 1 or 2 points?**  
14  
15  
16

17  
18  
19 Peter Brønnum Nielsen, MSc, PhD<sup>1</sup>

20  
21 Torben Bjerregaard Larsen, MD, PhD<sup>1</sup>

22  
23 Gregory Y.H. Lip, MD<sup>1,2</sup>

24  
25  
26 1. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg  
27 University, Aalborg, Denmark

28  
29  
30 2. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,  
31 United Kingdom  
32  
33  
34

35  
36  
37 **Running title:** Recalibration of the HAS-BLED score

38  
39  
40  
41 **Correspondence to:** Prof GYH Lip.

42  
43 g.y.h.lip@bham.ac.uk  
44  
45  
46

47  
48 **Funding and role of the sponsor:**

49  
50 The Obel Family Foundation partly funded this research by an unrestricted grant. The sponsor had  
51 no role the design and conduct of the study; collection, management, analysis, and interpretation of  
52 the data; and preparation, review, or approval of the manuscript.  
53  
54  
55  
56  
57  
58  
59  
60

**Disclosures**

Professor Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer and Boehringer Ingelheim, and has been on the speaker bureaus for Bayer, BMS/Pfizer, Boehringer Ingelheim and Sanofi. Associate Professor Larsen has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim, and has been on the speaker bureaus for Bayer, BMS/Pfizer, Roche Diagnostics, Boehringer Ingelheim and Takeda Pharma. Other authors – none declared

**Abstract**

Following a haemorrhagic stroke, it is uncertain whether this event scores 1 point (either for Stroke or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a haemorrhagic stroke.

We analysed data from the Danish nationwide cohort of incident atrial fibrillation (AF) patients from January 1999 to December 2013. The primary outcome in this observational study was major bleeding. The original- and the recalibrated HAS-BLED scores were assessed and event rates of major bleeding were calculated. We compared the predictive accuracy of major bleeding by C-statistics, the Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI).

In a total of 210,299 AF patients, we observed an event rate for major bleeding of 4.3 per 100 person-years. The C-statistics for the two scores were modest: 0.613 (95%CI, 0.607-0.619) for the original and 0.616 (95%CI, 0.610-0.622) for the recalibrated. The NRI was 10.0% (95%CI 7.6%-12.4%). When assessing the NRI in less than 6 months follow-up, we observed a markedly higher NRI of 34.2%. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) reflecting that the recalibrated HAS-BLED score more accurately predicted bleeding events.

Recalibration of the “S” component in the HAS-BLED score, counting 2 points for a haemorrhagic stroke, resulted in an increase in the C-statistics, NRI and IDI. This approach could potentially aid physicians in a more accurate bleeding risk assessment in AF patients.

## Introduction

Oral anticoagulant (OAC) treatment substantially reduces the risk of stroke and all-cause mortality in atrial fibrillation (AF) patients.<sup>1</sup> However, the decision to treat these patients relies on the expected risk of stroke weighed against the expected risk of bleeding. Contemporary guideline recommendations on OAC treatment are based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score (assessing the risk of thromboembolism) to initiate treatment or not.<sup>2,3</sup> The European Society of Cardiology further recommends formal assessment of the bleeding risk by the HAS-BLED score.<sup>4</sup> The HAS-BLED score summarizes to a maximum of 9 points (hypertension, abnormal renal/liver function [1 or 2 points], stroke, bleeding history or predisposition, labile INR, elderly [ $>65$ ], drugs/alcohol concomitantly [1 or 2 points]).<sup>5</sup> A stroke currently contributes 1 point, and prior major bleeding (or its predisposition) contributes 1 point. Accurate bleeding risk assessment and optimal treatment guidance is pivotal in this frail population of AF patients who sustain an intracranial bleeding, especially given the strong associations to disability and mortality.<sup>6,7</sup>

Following a haemorrhagic stroke, it is unclear whether it should count 1 point (either for Stroke or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a haemorrhagic stroke.

## Methods and materials

We used data from three Danish nationwide registries to conduct an observational cohort study investigating the original HAS-BLED score and the recalibrated HAS-BLED score. As previously done, we identified nonvalvular AF patients discharged from hospital from January 1<sup>st</sup> 1999 to December 31<sup>st</sup> 2013, and excluded patients who encountered a thromboembolism or major bleeding within 7 days after discharged.<sup>8</sup> The primary endpoint was major bleeding defined as a composite of intracranial bleeding (including traumatic intracranial bleeding events), gastrointestinal bleeding, acute anemia, bleeding from the urinary tract, and airway bleeding; see supplemental e-Table 1 for ICD-10 codes. Both primary and secondary diagnoses were included, but emergency room diagnoses were not included due to low validity.<sup>9</sup> We followed the patients from 7 days after hospital discharge and up to one year later or to occurrence of death, a major bleeding event, or end-of-study period, whichever came first.

We calculated two different HAS-BLED scores (original and recalibrated) at hospital discharge; only patients with a haemorrhagic stroke (non-traumatic intracranial bleeds) were reclassified in the recalibrated HAS-BLED score. Crude event rates (total number of events divided by accrued person-time) stratified by score ranging from 0-8 were reported. We did not have information on INR values; hence the “L” component was excluded from the calculations. To compare the predictive power of the scores we calculated and compared the (Harrell’s) C-statistics.<sup>10</sup> We obtained estimates of bleeding risk in a competing risk of death setting, by using information directly from the cumulative incidence function.<sup>11</sup> Use of competing risk analyses are advised - especially in an elderly and fragile population - to obtain adequate risk estimates, which are not biased due to the competing risk.<sup>12</sup> To further compare the individual level changes in risk assessment from the two scores, we calculated a Net Reclassification Index (NRI), also in a competing risk setting.<sup>13,14</sup> In short, the NRI evaluates the proportion of patients with a

1  
2  
3  
4 correct/incorrect change in risk according to being a case (patient with an event) or a non-case.

5  
6 Finally, we calculated the Integrated Discrimination Improvement (IDI) relative to the original  
7  
8 HAS-BLED score to assess the separation in predicted risk for events and non-events.<sup>15</sup> Bootstrap  
9  
10 confidence intervals (CI) for C-statistics, NRI and IDI were calculated using 100 bootstrap samples.  
11  
12 Data were analysed using Stata version 13.1 (Stata Corporation, College Station, TX). Register-  
13  
14 based studies do not require ethical approval in Denmark.  
15  
16

17  
18 We performed three sensitivity analyses, as follows: 1) stratifying patients according to baseline  
19  
20 OAC treatment or initiation within the first 7 days after baseline. This was done in an attempt to  
21  
22 indirectly assess if the missing “L” component from the data could influence the results  
23  
24 (recognizing that patients not treated with OAC would not contribute to this component); 2)  
25  
26 restricting the follow-up time to 6 months to assess performance of the recalibrated HAS-BLED  
27  
28 compared to the original HAS-BLED in (relatively) short follow-up time. The motivation for this  
29  
30 analysis was established by conceding an intracranial haemorrhage can be associated with increased  
31  
32 event rates of recurrent major bleeding (including recurrent intracranial bleeding)<sup>16</sup>; and 3), we  
33  
34 restricted the study period to the five most recent calendar years (2009-2013). Given the increasing  
35  
36 availability of imaging technologies (MRI/CT scans) in this period, the validity of haemorrhagic  
37  
38 stroke and/or haemorrhagic bleedings diagnosis were deemed to increase; hence, the proportion of  
39  
40 reclassified patients (based on haemorrhagic stroke) would be more accurate.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

The study population comprised 210,299 AF patients (5,898 patients were excluded due to a thromboembolic/bleeding event within 7 days after discharge) with a median age of 74 [IQR: 65-82] and 46.6% were women. During one year of follow-up we observed 7,602 (3.62%) bleeding events. The mean HAS-BLED scores were 2.13 for the original score and 2.14 for the recalibrated score. The overall crude event rate of the primary endpoint was 4.3 per 100 person-years; Table 1 shows the event rates stratified according to points for the two scores. A total of 1,479 patients were reclassified in the recalibrated HAS-BLED score based on having sustained a haemorrhagic stroke when the observation time commenced. The predictive accuracy of the two scores in terms of the C-statistics was moderate, 0.613 (95%CI, 0.607-0.619) for the original and 0.616 (95%CI, 0.610-0.622) for the recalibrated HAS-BLED score, respectively. The NRI was 10.0% (95%CI, 7.6%-12.4%) displaying a significant improvement of correct classification by the recalibrated HAS-BLED score compared to the original score. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) reflecting that the recalibrated HAS-BLED score more accurately predicted bleeding events.

When stratifying the cohort to patients who received no OAC treatment vs treated, we saw an increase in the bleeding rates per 100 person-years: 3.97 for no treatment and 4.73 for OAC treated. The sensitivity analysis resulted in similar NRI: for OAC treated 9.0% (95%CI, 4.8%-12.3%) and for not treated 10.1% (95%CI, 9.0%-11.2%). The C-statistics were likewise not affected by this stratification [data not shown]. When applying shorter follow-up period (i.e. 6 months), we observed a considerably higher NRI of 35.0% (95%CI, 32.9%-37.1%). The C-statistics for original and recalibrated HAS-BLED score, however, displayed a modest increase, 0.617 and 0.621, respectively. Restricting the study period to the last five years reduced the study population to 78,699 patients, and essentially doubled the NRI: 20.7% (95%CI, 17.9%-23.5%).



## Discussion

In this nationwide cohort study reflecting clinical practice, we recalibrated the original HAS-BLED score to account for 2 points if the stroke type was a haemorrhagic stroke. We observed an improved accuracy of the recalibrated HAS-BLED score as displayed by an improved NRI of 10.0% and a relative IDI of 23%.

Although the recalibration only resulted in a modest increase in the C-statistics, the potential of improved accuracy could be higher, as we only reclassified a very small proportion of this large cohort: of 2,218 patients who sustained an ICH event, we reclassified 1,479 (0.7% of total study population). The remaining 739 patients who were not reclassified all had prior events of ischemic stroke/TIA and a major bleeding event (or anaemia).

The recalibrated HAS-BLED score could potentially be more complicated to count than the original score. The physician who is presented with a patient who has sustain an haemorrhagic stroke has to take into account if this patient already has 1 point attributing prior bleeding and prior stroke. On the other hand, counting a haemorrhagic stroke as two points (1 for stroke and 1 for bleeding) appears intuitively applicable given the nature of the outcome. Importantly, the recalibrated score performs best within short follow-up time in terms of NRI, which could be related to the patients who were actually reclassified (those with a haemorrhagic stroke); however, this could represent the early excess risk associated with such 'high risk' patients.

This study has some limitations. We did not have access to INR values from the registries; hence we excluded a potential pivotal component from the HAS-BLED score. We used an observational design to assess the HAS-BLED score, but we cannot rule out miscoding of comorbidity and concomitant medication. Additionally, we did not have access to imaging data and we cannot rule out erroneously coded haemorrhagic strokes. We assessed the HAS-BLED score at baseline,

1  
2  
3  
4 however risk assessment in AF patients is a continuum and risk (both for bleeding and  
5  
6 thromboembolic events) does not remain static in these patients.  
7  
8

9  
10 In conclusion, recalibration of the HAS-BLED score, counting 2 points for a haemorrhagic stroke,  
11  
12 resulted in an improved accuracy of predicting major bleeding events. This approach could  
13  
14 potentially aid physicians in a more accurate bleeding risk assessment in AF patients.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;146(12):857–67.
2. Camm AJ, Lip GYH, Caterina R De, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation - Developed with the special contribution of the European Heart Rhythm Association. *Europace* 2012;14(10):1385–413.
3. January CT, Wann FLS, Joseph F, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. *J Am Coll Cardiol* 2014;64(21):2246–2280.
4. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;31(19):2369–429.
5. Pisters R, Lane DA, Nieuwlaat R, Vos CB de, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138(5):1093–100.
6. Marsh EB, Gottesman RF. Brain hemorrhage: restarting anticoagulation after intracranial hemorrhage. *Nat Rev Neurol* 2011;7(3):130–2.
7. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GYH. Restarting Anticoagulant Treatment After Intracranial Haemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality and Bleeding: A Nationwide Cohort Study. *Circulation* 2015;In press. DOI 10.1161/CIRCULATIONAHA.115.015735
8. Lip GYH, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide co. *Chest* 2014;146(5):1337–46.
9. Johnsen SP, Overvad K, Sørensen HT, Tjønneland A, Husted SE. Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. *J Clin Epidemiol* 2002;55(6):602–7.
10. Newson R. Comparing the predictive powers of survival models using Harrell's C or Somers' D. *Stata J* 2010;10(3):339–358.
11. Wolbers M, Koller MT, Wittman JCM, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiology* 2009;20(4):555–561.

12. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy: A competing risk study. *Circulation* 2008;117(15):1918–1926.
13. Pencina MJ, D’Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med* 2011;30(1):11–21.
14. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. *Biometrics* 2005;61(1):223–229.
15. Pencina MJ, D’Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. *Clin. Chem. Lab. Med.* 2010;48(12):1703–1711.
16. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. *Mayo Clin Proc* 2007;82(1):82–92.

**Table 1:** Major bleeding event rates per 100 person-years for major bleeding events according to HAS-BLED scores for 1-year follow-up in incident atrial fibrillation patients.

Points	Original HASBLED			Recalibrated HASBLED		
	Person-time	Events	Event rate	Person-time	Events	Event rate
0	19611	193	0.98	19611	193	.98
1	41864	1127	2.69	41799	1,111	2.69
2	51933	2179	4.20	51703	2,149	4.16
3	43769	2392	5.46	43646	2,368	5.43
4	17359	1294	7.45	17472	1,316	7.53
5	3692	361	9.78	3965	402	10.14
6	425	52	12.25	456	59	12.94
7	22	4	18.23	23	4	17.36
8	12	0	-	22	0	-
9 (Labile INR)	NA	NA	NA	NA	NA	NA
Any score	178676	7602	4.3	-	-	-
Categorised risk						
0-2 (low risk)	113408	3499	3.09	113113	3453	3.05
≥3 (High risk)	65268	4103	6.29	65563	4149	6.33

Observation time starts after a quarantine period of 7 days relative to AF discharge.

**e-Table 1:** ICD codes and ATC codes used in the study.

Condition	International Classification of Diseases 10th revision (ICD-10) code	Anatomical Therapeutic Chemical (ATC) code
Hypertension	E10.0; E10.1; E10.9; E11.0; E11.1; E11.9	See specified definition* A10
Diabetes mellitus	E10.0; E10.1; E10.9; E11.0; E11.1; E11.9	A10
Ischemic stroke	I63; I64	
Transient ischemic disease	G45	
Abnormal renal function	I12; I13; N00-N05; N07; N11; N14; N17-N19; Q61	
Abnormal hepatic function	B15.0; B16.0; B16.2; B19.0; K70.4; K72; K76.6; I85	
Prior Bleeding	I60-I62; D62; J94.2; H11.3; H35.6; H43.1; N02; N95; R04; R31; R58; K25.0; K26.0; K27.0; K28.0; K29.0; S06.3C; S06.4; S06.5; S06.6	
Alcohol intake	E22.4; E52.9A; F10; G31.2; G62.1; G72.1; I42.6; K29.2; K70; K86.0; L27.8A; O35.4M; T51; Z71.4; Z72.1	
Atrial fibrillation	I48	
Major bleeding	D62 J942 H113 H356 H431 N02 N95 R04 R31 R58	
Gastrointestinal bleeding	K250 K260 K270 K280 K290	
Intracranial bleeding	I60 I61 I62	
Traumatic intracranial bleeding	S063C S064 S065 S066	
Retinal bleeding	H356	
<b>Medication</b>		
Aspirin		B01AC06
Non-steroidal anti-inflammatory drugs		M01A

\* We identified subjects with hypertension from combination treatment with at least two of the following classes of antihypertensive Drugs:

I. Alpha adrenergic blockers (C02A, C02B, C02C)

II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52)

III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)

IV. Beta blockers (C07)

V. Calcium channel blockers (C07F, C08, C09BB, C09DB)

VI. Renin-angiotensin system inhibitors (C09).

151509

CHEST

Form  
Completion**CHEST AUTHOR AGREEMENT**

By submitting this *CHEST* Author Agreement and Conflict of Interest Disclosure ("Agreement") for the manuscript associated with this submission (the "Manuscript") I ("Author") represent, warrant and agree as follows:

- 1) I have participated sufficiently in the research and analysis of data, as well as the writing of the Manuscript, to take public responsibility for the Manuscript and to qualify as an "author" under *CHEST's* policies (available at <http://chestjournal.chestpubs.org> and referred to as the "Journal Publication Policies and Procedures")
- 2) All content included in the Manuscript is original and does not infringe the intellectual property rights or violate any other rights of others, including but not limited to, their rights under laws of contract, confidentiality, privacy, and defamation. If the Manuscript includes third-party tables, graphs or other content, written consents to use such materials have been obtained. The third-party consents will support print and on-line publication in *CHEST*, publication of supplements, translation into other languages, and other derivative uses and worldwide distribution of the Manuscript.
- 3) No portion of the Manuscript has been published previously or is under consideration for publication elsewhere. There has been full disclosure to *CHEST* of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the Manuscript.
- 4) There has been full disclosure to *CHEST* of all outside editorial assistance and the financial source of such assistance.
- 5) I have disclosed all conflicts of interest in accordance with the Journal Publication Policies and Procedures by completing the *CHEST* Conflicts of Interest Disclosure fields below. I agree to disclose any additional conflicts of interest that might arise between the time of my signing this Agreement and publication of the Manuscript in *CHEST*.
- 6) To the best of my knowledge, there has been full disclosure to *CHEST* of all data and events, including adverse events and changes to the protocol, that are relevant and material to the study results and/or other content of the Manuscript.
- 7) I have read and understand all of the Journal Publication Policies and Procedures.
- 8) I hereby assign to The American College of Chest Physicians ("ACCP") all of my right, title, and interest, specifically including copyright rights, in and to the Manuscript. This assignment will occur automatically, without notice or further action, upon acceptance of the Manuscript for publication in *CHEST*. Notwithstanding the foregoing, if I am a federal employee, I will retain copyright in the Manuscript, and I have indicated this in the Acknowledgments section of the manuscript.
- 9) The Manuscript, all information provided in *CHEST* ScholarOne Manuscripts, and all information accompanying the submission are true and complete in all respects, and comply with *CHEST's* Author Instructions.
- 10) I have not and will not, prior to publication, report scientific information described in the Manuscript to public media. I will submit any new data or information that is relevant and material to the study results and/or other content of the Manuscript, if it becomes available between the time of my signing this Agreement and publication of the Manuscript in *CHEST*.
- 11) *CHEST* is participating in the NIH PubMed Central (NIH Portfolio) Archive. Those authors who publish NIH-funded papers in the Journal will not be obligated to submit manuscripts to PubMed Central because *CHEST* will submit the final article on their behalf.

No <sup>req</sup> This paper is the result in whole or in part of NIH-funded research and should be deposited in PubMed Central.

**CONFLICT OF INTEREST DISCLOSURES**

**DEFINITION:** For purposes of *CHEST* and this disclosure form, a conflict of interest is a financial relationship or other set of circumstances that might affect, or might reasonably be thought by others to affect, an author's judgment, conduct or manuscript. A conflict of interest exists based

on the author's circumstances. The author's **CHEST**, subjective beliefs, and outcomes are irrelevant. In other words, the author must disclose a conflict of interest, even if the circumstances do not actually influence the author's actions or manuscript, and even if the author believes that the circumstances cannot or will not affect the author's actions or manuscript.

**Category of Conflict of Interest**

Select each listed circumstance to indicate whether it applies to you or to your parents, siblings, spouse, life companion or children. (NOTE: Hold the CTRL key to select multiple items.) Consider the three-year time period before the date of this form and known, future commitments. Provide details in the text box below for all categories you select.

I have no Conflict of Interest to declare in relation to this manuscript.

Provide details for all categories selected above. Include dates, dollar amounts and other details.

Draft a conflicts of interest disclosure statement related to yourself, by summarizing all answers selected above in general terms (excluding specific monetary amounts); the summary that appears here should be included in the manuscript file:

**ATTESTATION:**

I attest that my answers are true, that I have disclosed all conflicts of interest in accordance with the *CHEST* publication and conflicts of interest policies (located at [http://www.chestjournal.org/site/misc/Policyinstrux9\\_2009.pdf](http://www.chestjournal.org/site/misc/Policyinstrux9_2009.pdf)), and that the disclosed conflicts of interest (if any) did not bias, or in any way impact the integrity of, the submitted manuscript.

**Agree**

By clicking the "Agree" button, I attest that the statements entered into this electronic record are true, accurate, and complete.

By typing my name into this field, I am confirming that I am the person whose ScholarOne Manuscript account is logged into, and I understand that an electronic signature is taking place and I intend to be bound by this record.

Peter Brønnum Nielsen

 Print  Close Window



CHEST

Form  
Completion**CHEST AUTHOR AGREEMENT**

By submitting this *CHEST* Author Agreement and Conflict of Interest Disclosure ("Agreement") for the manuscript associated with this submission (the "Manuscript") I ("Author") represent, warrant and agree as follows:

**1)** I have participated sufficiently in the research and analysis of data, as well as the writing of the Manuscript, to take public responsibility for the Manuscript and to qualify as an "author" under *CHEST's* policies (available at <http://chestjournal.chestpubs.org> and referred to as the "Journal Publication Policies and Procedures")

**2)** All content included in the Manuscript is original and does not infringe the intellectual property rights or violate any other rights of others, including but not limited to, their rights under laws of contract, confidentiality, privacy, and defamation. If the Manuscript includes third-party tables, graphs or other content, written consents to use such materials have been obtained. The third-party consents will support print and on-line publication in *CHEST*, publication of supplements, translation into other languages, and other derivative uses and worldwide distribution of the Manuscript.

**3)** No portion of the Manuscript has been published previously or is under consideration for publication elsewhere. There has been full disclosure to *CHEST* of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the Manuscript.

**4)** There has been full disclosure to *CHEST* of all outside editorial assistance and the financial source of such assistance.

**5)** I have disclosed all conflicts of interest in accordance with the Journal Publication Policies and Procedures by completing the *CHEST* Conflicts of Interest Disclosure fields below. I agree to disclose any additional conflicts of interest that might arise between the time of my signing this Agreement and publication of the Manuscript in *CHEST*.

**6)** To the best of my knowledge, there has been full disclosure to *CHEST* of all data and events, including adverse events and changes to the protocol, that are relevant and material to the study results and/or other content of the Manuscript.

**7)** I have read and understand all of the Journal Publication Policies and Procedures.

**8)** I hereby assign to The American College of Chest Physicians ("ACCP") all of my right, title, and interest, specifically including copyright rights, in and to the Manuscript. This assignment will occur automatically, without notice or further action, upon acceptance of the Manuscript for publication in *CHEST*. Notwithstanding the foregoing, if I am a federal employee, I will retain copyright in the Manuscript, and I have indicated this in the Acknowledgments section of the manuscript.

**9)** The Manuscript, all information provided in *CHEST* ScholarOne Manuscripts, and all information accompanying the submission are true and complete in all respects, and comply with *CHEST's* Author Instructions.

**10)** I have not and will not, prior to publication, report scientific information described in the Manuscript to public media. I will submit any new data or information that is relevant and material to the study results and/or other content of the Manuscript, if it becomes available between the time of my signing this Agreement and publication of the Manuscript in *CHEST*.

**11)** *CHEST* is participating in the NIH PubMed Central (NIH Portfolio) Archive. Those authors who publish NIH-funded papers in the Journal will not be obligated to submit manuscripts to PubMed Central because *CHEST* will submit the final article on their behalf.

No <sup>req</sup> This paper is the result in whole or in part of NIH-funded research and should be deposited in PubMed Central.

**CONFLICT OF INTEREST DISCLOSURES**

**DEFINITION:** For purposes of *CHEST* and this disclosure form, a conflict of interest is a financial relationship or other set of circumstances that might affect, or might reasonably be thought by others to affect, an author's judgment, conduct or manuscript. A conflict of interest exists based

on the author's circumstances. The author's **CHEST**, subjective beliefs, and outcomes are irrelevant. In other words, the author must disclose a conflict of interest, even if the circumstances do not actually influence the author's actions or manuscript, and even if the author believes that the circumstances cannot or will not affect the author's actions or manuscript.

### Category of Conflict of Interest

Select each listed circumstance to indicate whether it applies to you or to your parents, siblings, spouse, life companion or children. (NOTE: Hold the CTRL key to select multiple items.) Consider the three-year time period before the date of this form and and known, future commitments. Provide details in the text box below for all categories you select.

Participate in speaking activities, an industry advisory committee, or other activities related to industry sources, with or without receiving honoraria or in-kind benefits

I have no Conflict of Interest to declare in relation to this manuscript.

Provide details for all categories selected above. Include dates, dollar amounts and other details.

Draft a conflicts of interest disclosure statement related to yourself, by summarizing all answers selected above in general terms (excluding specific monetary amounts); the summary that appears here should be included in the manuscript file:

Has served as an investigator for Janssen Scientific Affairs LLC and Boehringer Ingelheim GmbH, and have been on the speaker bureaus for Bayer AG, Bristol-Myers Squibb Co/Pfizer Inc, Roche Diagnostics Corp, Boehringer Ingelheim GmbH, and Takeda Pharmaceutical Co Ltd.

### ATTESTATION:

I attest that my answers are true, that I have disclosed all conflicts of interest in accordance with the *CHEST* publication and conflicts of interest policies (located at [http://www.chestjournal.org/site/misc/Policyinstrux9\\_2009.pdf](http://www.chestjournal.org/site/misc/Policyinstrux9_2009.pdf)), and that the disclosed conflicts of interest (if any) did not bias, or in any way impact the integrity of, the submitted manuscript.

### Agree

By clicking the "Agree" button, I attest that the statements entered into this electronic record are true, accurate, and complete.

By typing my name into this field, I am confirming that I am the person whose ScholarOne Manuscript account is logged into, and I understand that an electronic signature is taking place and I intend to be bound by this record.

Torben Bjerregaard Larsen

 Print  Close Window

CHEST

Form  
Completion**CHEST AUTHOR AGREEMENT**

By submitting this *CHEST* Author Agreement and Conflict of Interest Disclosure ("Agreement") for the manuscript associated with this submission (the "Manuscript") I ("Author") represent, warrant and agree as follows:

**1)** I have participated sufficiently in the research and analysis of data, as well as the writing of the Manuscript, to take public responsibility for the Manuscript and to qualify as an "author" under *CHEST*'s policies (available at <http://chestjournal.chestpubs.org> and referred to as the "Journal Publication Policies and Procedures")

**2)** All content included in the Manuscript is original and does not infringe the intellectual property rights or violate any other rights of others, including but not limited to, their rights under laws of contract, confidentiality, privacy, and defamation. If the Manuscript includes third-party tables, graphs or other content, written consents to use such materials have been obtained. The third-party consents will support print and on-line publication in *CHEST*, publication of supplements, translation into other languages, and other derivative uses and worldwide distribution of the Manuscript.

**3)** No portion of the Manuscript has been published previously or is under consideration for publication elsewhere. There has been full disclosure to *CHEST* of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the Manuscript.

**4)** There has been full disclosure to *CHEST* of all outside editorial assistance and the financial source of such assistance.

**5)** I have disclosed all conflicts of interest in accordance with the Journal Publication Policies and Procedures by completing the *CHEST* Conflicts of Interest Disclosure fields below. I agree to disclose any additional conflicts of interest that might arise between the time of my signing this Agreement and publication of the Manuscript in *CHEST*.

**6)** To the best of my knowledge, there has been full disclosure to *CHEST* of all data and events, including adverse events and changes to the protocol, that are relevant and material to the study results and/or other content of the Manuscript.

**7)** I have read and understand all of the Journal Publication Policies and Procedures.

**8)** I hereby assign to The American College of Chest Physicians ("ACCP") all of my right, title, and interest, specifically including copyright rights, in and to the Manuscript. This assignment will occur automatically, without notice or further action, upon acceptance of the Manuscript for publication in *CHEST*. Notwithstanding the foregoing, if I am a federal employee, I will retain copyright in the Manuscript, and I have indicated this in the Acknowledgments section of the manuscript.

**9)** The Manuscript, all information provided in *CHEST* ScholarOne Manuscripts, and all information accompanying the submission are true and complete in all respects, and comply with *CHEST*'s Author Instructions.

**10)** I have not and will not, prior to publication, report scientific information described in the Manuscript to public media. I will submit any new data or information that is relevant and material to the study results and/or other content of the Manuscript, if it becomes available between the time of my signing this Agreement and publication of the Manuscript in *CHEST*.

**11)** *CHEST* is participating in the NIH PubMed Central (NIH Portfolio) Archive. Those authors who publish NIH-funded papers in the Journal will not be obligated to submit manuscripts to PubMed Central because *CHEST* will submit the final article on their behalf.

No <sup>req</sup> This paper is the result in whole or in part of NIH-funded research and should be deposited in PubMed Central.

**CONFLICT OF INTEREST DISCLOSURES**

**DEFINITION:** For purposes of *CHEST* and this disclosure form, a conflict of interest is a financial relationship or other set of circumstances that might affect, or might reasonably be thought by others to affect, an author's judgment, conduct or manuscript. A conflict of interest exists based

on the author's circumstances. The author's **CHEST**, subjective beliefs, and outcomes are irrelevant. In other words, the author must disclose a conflict of interest, even if the circumstances do not actually influence the author's actions or manuscript, and even if the author believes that the circumstances cannot or will not affect the author's actions or manuscript.

### Category of Conflict of Interest

Select each listed circumstance to indicate whether it applies to you or to your parents, siblings, spouse, life companion or children. (NOTE: Hold the CTRL key to select multiple items.) Consider the three-year time period before the date of this form and and known, future commitments. Provide details in the text box below for all categories you select.

I have no Conflict of Interest to declare in relation to this manuscript.

Provide details for all categories selected above. Include dates, dollar amounts and other details.

Draft a conflicts of interest disclosure statement related to yourself, by summarizing all answers selected above in general terms (excluding specific monetary amounts); the summary that appears here should be included in the manuscript file:

#### DECLARATION OF INTERESTS

Guideline membership/reviewing: ESC Guidelines on Atrial Fibrillation, 2010 and Focused Update, 2012; ESC Guidelines on Heart Failure, 2012; American College of Chest Physicians Antithrombotic Therapy Guidelines for Atrial Fibrillation, 2012; NICE Guidelines on Atrial Fibrillation, 2006 and 2014; NICE Quality Standards on Atrial Fibrillation 2015; ESC Cardio-oncology Task Force, 2015; ESC Working Group on Thrombosis position documents (2011-). Chairman, Scientific Documents Committee, European Heart Rhythm Association (EHRA). Reviewer for various guidelines and position statements from ESC, EHRA, NICE etc.

Steering Committees/trials: Includes steering committees for various Phase II and III studies, Health Economics & Outcomes Research, etc. Investigator in various clinical trials in cardiovascular disease, including those on antithrombotic therapies in atrial fibrillation, acute coronary syndrome, lipids, etc.

Consultant/Advisor/Speaker:

Consultant for Bayer/Jensen J&J, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.

Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo

#### ATTESTATION:

I attest that my answers are true, that I have disclosed all conflicts of interest in accordance with the *CHEST* publication and conflicts of interest policies (located at [http://www.chestjournal.org/site/misc/Policyinstrux9\\_2009.pdf](http://www.chestjournal.org/site/misc/Policyinstrux9_2009.pdf)), and that the disclosed conflicts of interest (if any) did not bias, or in any way impact the integrity of, the submitted manuscript.

#### Agree

By clicking the "Agree" button, I attest that the statements entered into this electronic record are true, accurate, and complete.

By typing my name into this field, I am confirming that I am the person whose ScholarOne Manuscript account is logged into, and I understand that an electronic signature is taking place and I intend to be bound by this record.

Gregory Lip

 Print  Close Window

**ARTICLE TRANSMITTAL CHECKLIST –**

Article Title: Recalibration of the HAS-BLED score – should haemorrhagic stroke account for 1 or 2 points?

PIT (Publication Item Type): DIS

First Author Information (name, contact info, email):

Peter Bronnum Nielsen, MSc

Aalborg Thrombosis Research Unit

Dept of Clinical Medicine

Faculty of Health

Aalborg University

Aalborg, Denmark

pbn@rn.dk

Corresponding Author Information (name, contact info, email):

Gregory Lip, MD

City Hospital - Centre for Cardiovascular Sciences

Dudley Road , Birmingham B18 7QH

United Kingdom

g.y.h.lip@bham.ac.uk

Manuscript file (accept all changes/turn off track changes):

[Recalibration of the HAS-BLED score 070715 clean.rev.docx \(v1.0\)](#)

[List of abbreviations.docx \(v1.0\)](#)

Figure files (must be separate files; cannot be embedded): N/A

Supplemental Online Files (videos and other e-components):

[Data Supp 151509.pdf \(v1.0\)](#)

Disclosure forms (scan as 1 PDF and upload):

[CHEST-15-1509-COI.pdf \(v1.0\)](#)

Permissions (if applicable) (scan as 1 PDF and upload): N/A

Conflict of Interest Statements (if not part of the disclosure form):

1  
2  
3 Running Head: Recalibration of the HAS-BLED score  
4

5 Issue Designation:  
6

7 Notes/Remarks – Online content only  
8

9 Does this article refer to another article, and should it link to the article? No  
10

11 List any author who still needs to submit a disclosure form: n/a  
12

13 Embargo required?  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60